ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer
详细信息 查看全文
- 作者：Marco Napoli1 ; 2 ; Avinashnarayan Venkatanarayan1 ; 2 ; 3 ; Payal Raulji1 ; 2 ; Brooke A. Meyers1 ; 2 ; William Norton4 ; Lingegowda S. Mangala5 ; 6 ; Anil K. Sood5 ; 6 ; Cristian Rodriguez-Aguayo6 ; 7 ; Gabriel Lopez-Berestein6 ; 7 ; Harina Vin8 ; Madeleine Duvic8 ; Michael B. Tetzlaff8 ; 9 ; Jonathan L. Curry8 ; 9 ; Alain H. Rook10 ; Hussein A. Abbas1 ; 2 ; Cristian Coarfa11 ; Preethi H. Gunaratne12 ; Kenneth Y. Tsai2 ; 3 ; 8 ; Elsa R. Flores1 ; 2 ; 3 ; 6 ; elsaflores@mdanderson.org" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：13 June 2016
- 年：2016
- 卷：29
- 期：6
- 页码：874-888
- 全文大小：4096 K
文摘
- •
HDAC inhibitors (HDACi) reduce ΔNp63 stability in an Fbw7-dependent manner
- •
HDACi cause tumor regression by impairing ΔNp63/DGCR8-dependent miRNA maturation
- •
Fbw7 levels are predictive of tumor response to HDACi
- •
Resistance to HDACi can be bypassed by direct inhibition of let-7d and miR-128